Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo.

Biomedicines · 2022 · PMC8945459 · PMID 35327426

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The HSP90 inhibitor 17-DMAG showed the greatest in vivo effect in our MLS PDX model, whereas AUY922 showed a trend towards increased tumor growth and a more aggressive tumor morphology.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.